ClinicalTrials.gg
CompletedNCT03765697Updated Sep 13, 2023

A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia

A Phase 3 interventional study of Lidocaine 5% medicated plaster in Post Herpetic Neuralgia, sponsored by Grünenthal GmbH. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Grünenthal GmbH · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 15 years 4 months after the study started (first participant enrolled Jul 2003, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
259
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

This study was performed to evaluate the local and systemic safety profile and the analgesic efficacy of long-term treatment with lidocaine 5% medicated plaster (Lido-Patch).

The study was an open-label, multi-center, multiple-dose, Phase III study and comprised a main and an extension period. 161 participants who completed treatment in KF10004/01 (NCT03745404) and 98 newly recruited participants were enrolled.

Read the detailed description

The main period was performed in 34 sites in 12 European countries (259 participants). Treatment duration was up to 12 months. All participants applied lidocaine 5% medicated plaster (containing 700 mg lidocaine per plaster) topically at the site of the skin affected by painful PHN. Depending on the size of the affected skin area, up-to 3 plasters were simultaneously applied for up to 12 hours per day (with a plaster-free interval of at least 12 hours). Study objectives of the main period were to evaluate the local and systemic safety profile and the analgesic efficacy of lidocaine 5% medicated plaster, and to evaluate the pharmacokinetics of lidocaine and its metabolite 2,6-xylidine in the target population after multiple administrations of lidocaine 5% medicated plaster by means of population kinetics. The study results were planned to be evaluated descriptively.

102 participants who were satisfied with the treatment in the main study period entered the open-label extension period with continued treatment. 27 sites in 12 countries participated in the extension period. Enrollment in the extension period coincided with last visit of the main period of the study. Treatment duration was up to 4.4 years in the extension period. The objective of the extension period was to evaluate the long-term local and systemic safety profile and the long-term analgesic efficacy of treatment with lidocaine 5% medicated plaster in the subpopulation who had completed 12 months of treatment in the open-label main study period.

02

Conditions studied

  • Post Herpetic Neuralgia

Keywords

  • post-herpetic neuralgia
  • lidocaine
03

In context

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

This study's enrollment of 259 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.

Browse Neuralgia, Postherpetic studies →

Lead sponsor

Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, male and female, with a minimum age of 50 years at screening.
  • Participants who had postherpetic neuralgia (PHN) for at least 3 months after healing of a herpes zoster skin rash.
  • Only for patients who had not participated in the KF10004/01 (NCT03745404) study: Pain score of at least 4, based on an 11-point numerical rating scale (NRS) (scale of 0-10), at the screening visit. The pain assessment is the participant's recall of the pain intensity since the previous week.
  • Written given.

Exclusion criteria

Exclusion Criteria:

  • Participation in another study of drugs or devices parallel to, or less than 30 days before screening, or previous participation in this study, except previous participation in the KF10004/01 study.
  • Known to or suspected of not being able to comply with the study protocol.
  • Any condition that would, in the investigator's opinion, preclude study participation for instance alcohol, medication or drug dependency, neurotic personality, psychiatric illness, epilepsy or suicide risk.
  • Pregnancy or nursing mother.
  • Woman in childbearing age without satisfactory .
  • to lidocaine or amide-type local anesthetic drugs.
  • Active herpes zoster lesion or dermatitis of any origin at the affected site with PHN.
  • Evidence of another cause for pain in the area affected by herpes zoster in addition to PHN, such as lumbar radiculopathy, surgery or trauma, if this could confound assessment or self-evaluation of the pain due to PHN.
  • Participants who had neurological ablation by block or neurosurgical intervention for control of pain in PHN.
  • Participants using topically applied analgesic compounds on the PHN affected area.
  • Presence of other severe pain that could confound assessment or self-evaluation of the pain due to PHN.
  • Participants with severe hepatic disorder and/or alanine or equal to or above 3-fold the (ULN).
  • Participants with severe renal disorder and/or increased serum creatinine equal to or above 1.5-fold the upper limit of normal (ULN).
  • Participants who are undergoing active treatment for cancer, are known to be infected with the (HIV), or being acutely and intensively following transplantation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
259 participants (actual)

Study arms

  • Experimental
    Lidocaine 5% medicated plaster

    Up to 3 plasters were applied per day.

    Drug: Lidocaine 5% medicated plaster

Interventions

  • Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).

    Also known as: Versatis (Trade Mark), Neurodol Tissugel (Trade Mark), Lidoderm (Trade Mark)

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent adverse events (main study period)

    Treatment emergent adverse events (TEAEs) were continually monitored through the main period of the study (12 months). Incidences were calculated based on all events reported up to 12 months. No primary endpoint was defined for this study.

    Time frame: From first plaster application up to 12 months

Secondary outcomes

  1. Pain relief (main study period): verbal rating scale

    Pain relief was assessed starting 1 week (new participants) or 6 weeks after treatment initiation (participants from KF10004/01) until the final visit of the main study period. The average pain relief during the last week before the visit was assessed using a 6-item verbal rating scale (VRS) with categories 1 = worse, 2 = no pain relief, 3 = slight, 4 = moderate, 5 = a lot, and 6 = complete.

    Time frame: After 1, 6, 12, 18, 26, 34, 42, and 52 weeks (or early withdrawal)

  2. Pain intensity (main study period): Numeric Rating Scale

    The participant's recall of worst, least, and average pain intensity in the last week prior to each visit were assessed using an 11-point Numeric Rating Scale (NRS from 0 = no pain to 10 = pain as bad as you can imagine).

    Time frame: At screening/enrollment and after 1, 6, 12, 18, 26, 34, 42, and 52 weeks (or early withdrawal)

  3. Pain relief (extension period): verbal rating scale

    The participant's recall of average pain relief during plaster application in the last week prior to each visit in the extension period was assessed using a 6-item VRS with categories 1 = worse, 2 = no pain relief, 3 = slight, 4 = moderate, 5 = a lot, and 6 = complete.

    Time frame: Every 6 months after first plaster application in the extension period up to 4.4 years (or early withdrawal)

  4. Number of participants with treatment emergent adverse events (extension period)

    Treatment emergent adverse events were continually monitored for or asked about at each visit scheduled every 6 months in the extension period. The extension period lasted for up to 4.4 years and included a follow-up visit (1-2 weeks after last regular 6-month visit \[or early withdrawal\]). Adverse event incidences were calculated based on all events reported in the extension period.

    Time frame: Every 6 months after first plaster application in the extension period up to 4.4 years (including a follow-up visit 1-2 weeks after last regular 6-month visit or early withdrawal)

Other outcomes

  1. Allodynia severity rating (main study period)

    Allodynia severity was rated using the following categorical scale: 0 = no pain or discomfort to touch; 1 = uncomfortable, but tolerable to touch; 2 = painful; 3 = extremely painful, participant cannot stand touching. The test was conducted by means of a brush (type N12). The painful PHN area was stroked with the brush and the intensity of allodynic pain was assessed by the participant.

    Time frame: At screening/enrollment, and after 1, 6, 12, 18, 26, 34, 42, and 52 weeks (or early withdrawal)

  2. Clinical Global Impression of Change (CGIC) (main study period)

    Investigators were asked to describe their overall impression of the change of the participant's condition/pain by answering the following question: "Compared to the patient's condition at admission to the project, how much has he/she changed?" The categorical scale comprises the categories not assessed = 0, very much improved = 1, much improved = 2, minimally improved = 3, no change = 4, minimally worse = 5, much worse = 6, and very much worse = 7.

    Time frame: At 26 weeks of treatment in the main study period and at the final visit (at 52 weeks, or early withdrawal)

  3. Short Form-36 Quality of Life Index (SF-36) (main study period)

    The Short Form 36 Quality of Life Index (SF-36 \[Trade Mark\]) standard version with a 4-week recall period was used as a self-assessment. Eleven questions were answered on binomial (Yes/No) or on 3-, 5-, or 6-point categorical scales to generate the 8 raw scales (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health). Higher values of the raw scales represent a better outcome. The raw scales were converted into a transformed scale (transformed scale = \[(actual raw score - lowest possible raw score) / possible raw score range\] x 100).

    Time frame: At screening, and after 12, 26, 42, and 52 weeks (or early withdrawal)

  4. Short Form McGill Pain Questionnaire (SF-MPQ) (main study period)

    The SF-MPQ includes 15 words (11 sensory, 4 affective). Each word or phrase is rated on a 4-point intensity scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). In addition, the 6-point Present Pain Intensity (PPI) rating (no pain, mild, discomforting, distressing, horrible, excruciating) is included as is a visual analogue scale for rating pain intensity. Total score as well as sensory and affective sub-scores were calculated.

    Time frame: At screening, and after 12, 26, 42, and 52 weeks (or early withdrawal)

  5. Clinical Global Impression of Change (CGIC) (extension period)

    Investigators were asked to describe their overall impression of the change of the participant's condition/pain by answering the following question: "Compared to the patient's condition at admission to the project, how much has he/she changed?" (categories: not assessed = 0, very much improved = 1, much improved = 2, minimally improved = 3, no change = 4, minimally worse = 5, much worse = 6, very much worse = 7).

    Time frame: Every 6 months after first plaster application in the extension period up to 4.4 years (or early withdrawal)

  6. Patient's Global Impression of Change (PGIC) (extension period)

    Participants were asked to describe their overall impression of change of their condition/pain by answering the following question: "Compared to your pain at admission to the project, how much has it changed?" (categories: not assessed = 0, very much improved = 1, much improved = 2, minimally improved = 3, no change = 4, minimally worse = 5, much worse = 6, very much worse = 7).

    Time frame: Every 6 months after first plaster application in the extension period up to 4.4 years (or early withdrawal)

  7. Investigator's Global Evaluation of the IMP (extension period)

    The assessment of the investigational medicinal product (IMP) was made on a 5-point categorical scale (poor, fair, good, very good, excellent). Investigators responded to the following question: "How would you rate the study medication the patient received for pain?"

    Time frame: Every 6 months after first plaster application in the extension period up to 4.4 years (or early withdrawal)

  8. Patient's Global Evaluation of the IMP (extension period)

    The assessment of the IMP was made on a 5-point categorical scale (poor, fair, good, very good, excellent). Participants responded to the following question: "How would you rate the study medication you received for pain?"

    Time frame: Every 6 months after first plaster application in the extension period up to 4.4 years (or early withdrawal)

  9. Change in concomitant medication (main and extension period)

    For each participant, the number of different medications taken for PHN symptoms was determined at enrollment into the and at the last assessment in the study. Participants were classified into 5 groups: 0, 1, 2, 3, and more than 3 different substances taken. Shifts were determined for enrollment to last assessment in the study.

    Time frame: At enrollment into main study period; at last assessment in extension period (up to 5.4 years after enrollment)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Hans G, Sabatowski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009 May;25(5):1295-305. doi: 10.1185/03007990902901368. PubMed 19366301 ↗
  • Sabatowski R, Hans G, Tacken I, Kapanadze S, Buchheister B, Baron R. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 2012 Aug;28(8):1337-46. doi: 10.1185/03007995.2012.707977. Epub 2012 Jul 18. Erratum In: Curr Med Res Opin. 2014 Feb;30(2):329-30. PubMed 22769236 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2003 to primary completion in Jul 2005, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2018
First posted
Dec 5, 2018
StartActual
Jul 16, 2003
Primary completionActual
Jul 12, 2005
CompletionActual
Feb 12, 2009
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03765697
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Dec 5, 2018
Start date
Jul 16, 2003
Primary completion
Jul 12, 2005
Completion
Feb 12, 2009
Last update
Sep 13, 2023

Study contacts

Grünenthal Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion